A20 Promoter rs5029924 Concomitant with rs2230926 and rs5029937 May Be a Prognostic Predictor for Joint Deformity or Refractory Rheumatoid Arthritis
Lihua Zhu,Lingling Zhou,Liang Wang,Cunte Chen,Jie Qiao,Xinran Huang,Xiaoyan Su,Shaohua Chen,Bo Li,Xiuli Wu,Yangqiu Li
DOI: https://doi.org/10.2147/ijgm.s461561
IF: 2.145
2024-04-30
International Journal of General Medicine
Abstract:Lihua Zhu, 1, &ast Lingling Zhou, 2, 3, &ast Liang Wang, 4, &ast Cunte Chen, 2 Jie Qiao, 1 Xinran Huang, 1 Xiaoyan Su, 1 Shaohua Chen, 2 Bo Li, 2 Xiuli Wu, 2 Yangqiu Li 2 1 Department of Rheumatology and Immunology, First Affiliated Hospital, Jinan University, Guangzhou, 510632, People's Republic of China; 2 Institute of Hematology, School of Medicine, Key Laboratory for Regenerative Medicine of Ministry of Education, Jinan University, Guangzhou, 510632, People's Republic of China; 3 Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, 510632, People's Republic of China; 4 Department of Oncology, First Affiliated Hospital, Jinan University, Guangzhou, 510632, People's Republic of China &astThese authors contributed equally to this work Correspondence: Yangqiu Li, Institute of Hematology, School of Medicine, Key Laboratory for Regenerative Medicine of Ministry of Education, Jinan University, Guangzhou, 510632, People's Republic of China, Tel +86 20 85226877, Fax +86 20 85226877, Email Lihua Zhu, Department of Rheumatology and Immunology, First Affiliated Hospital, Jinan University, Guangzhou, 510632, People's Republic of China, Email Background: There have been several studies regarding the susceptibility of A20 gene SNPs (rs2230926 and rs5029937) in rheumatoid arthritis (RA). However, little is known about the association between polymorphisms in the A20 promoter and RA. The aim of this study was to investigate the characteristics of A20 promoter polymorphisms and the association between these polymorphisms and clinical significance in Chinese RA patients. Methods: PCR and sequencing were used to identify A20 gene polymorphisms in peripheral blood mononuclear cells (PBMCs) from 123 RA cases and 31 healthy individuals. Results: Only one SNP (rs5029924) in the A20 gene promoter was identified in RA patients and healthy individuals. 6 patients who carried heterozygous rs5029924 (3918C>T) together with heterozygous rs5029937 (11,571 G>T) and rs2230926 (12,486 T>G, Phe127Cys) suffered from joints deformity or refractory RA. Conclusion: We reported the A20 promoter polymorphism rs5029924 in RA patients for the first time. rs5029924 concomitant with rs2230926 and rs5029937 may be a prognostic predictor for joint deformity or refractory RA. Keywords: A20 , promoter, polymorphism, RA, deformity, refractory, predictor Rheumatoid arthritis (RA) is a systemic autoimmune inflammatory disease characterized by proliferative synovitis, the infiltration of inflammatory cells into synovial tissue, progressive joint destruction and disability.The mechanism underlying immune disorder in RA remains unclear. A20 ( TNFAIP3 ) is an important negative immunoregulatory gene located at 6q23. The intracellular ubiquitin-editing protein A20 is a key player in the negative feedback regulation of NF-kappa B signaling in response to multiple stimuli. Moreover, A20 also regulates tumor necrosis factor (TNF)-induced apoptosis. 1,2 Many A20 single nucleotide polymorphisms (SNPs) were found to be associated with the susceptibility to autoimmune disease. 3,4 Variants modulate the function of an enhancer upstream of TNFAIP3. 5 Little is known about the characteristics and incidence of A20 promoter polymorphisms in Chinese RA patients. 6,7 Therefore, we examined A20 promoter polymorphisms and explored the association between these polymorphisms and clinical significance in Chinese RA patients. Hospitalized adult RA patients came from the first Affiliated Hospital of Jinan University in 2015–2017. Rheumatologists diagnosed RA and these diagnoses also fulfilled the American College of Rheumatology criteria and expert opinion (1987 ACR criteria), 8 and / or 2010 ACR/EULAR Criteria. 9 The exclusion criteria for the RA patients was as follows: 1. Combined with other autoimmune diseases. 2. Combined with other internal medicine diseases (type 1 diabetes, type 2 diabetes, hypertension, chronic kidney disease and so on). 3. Patients with severe infections. 4. Patients with malignant tumors. 5. Smoking patients. All RA patients were assessed for clinical disease activity by a trained rheumatologist using disease activity score 28 (DAS 28). RA clinical assessment and blood sampling done were in the same day. The healthy individuals from our hospital physical examination center were in healthy status without smoking, any cancer, type 2 diabetes, hypertensio -Abstract Truncated-
medicine, general & internal